Generics - Valeant Pharmaceuticals, Actavis

Filter

Popular Filters

Actavis and Valeant report first quarter 2013 results

02-05-2013

US generics drug major Actavis (NYSE: ACT) and Canada's Valeant Pharmaceuticals (TSX: VRX) both presented…

ActavisFinancialGenericsValeant Pharmaceuticals

Actavis pays Valeant $55M for drug rights; Incyte gets $25M milestone

02-05-2013

US generics major Actavis (NYSE: ACT), reportedly the subject of a stalled takeover bid from Canada's…

ActavisAntibiotics and Infectious diseasesFinancialGenericsINC280IncyteLicensingMetronidazole LotionNovartisOncologyPharmaceuticalResearchValeant Pharmaceuticals

Actavis in OxyContin patent settlement; Valeant takeover bid "on hold"?

29-04-2013

US generic major Actavis (NYSE: ACT) has entered into an agreement with privately-held Purdue Pharma…

ActavisGenericsMergers & AcquisitionsNeurologicalNorth AmericaOxyContinPatentsPurdue PharmaValeant Pharmaceuticals

Actavis settles with Valeant to launch generic Ziana and Zyclara in USA

11-04-2013

US generics drug major Actavis (NYSE: ACT) has reached settlement agreements with Medicis Pharmaceutical,…

ActavisGenericsMarkets & MarketingNorth AmericaPatentsValeant PharmaceuticalsZiana GelZyclara

Actavis and Valeant to co-promote Zovirax and Cordran Tape

07-04-2013

Valeant Pharmaceuticals International (TSX: VRX) entered into an agreement, effective immediately, for…

ActavisAnti-viralsCordran TapeGenericsLicensingMarkets & MarketingMylan LaboratoriesNorth AmericaValeant PharmaceuticalsZovirax Ointment

Parexel

Parexel

Back to top